A Phase 1 interventional study of Atropine sulfate eye drops in Pharmacokinetics, sponsored by Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-11.
Sponsored by Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited (formerly part of Lee's Pharmaceutical Limited) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the systemic pharmacokinetics and the safety of atropine sulfate eye drops in healthy volunteers.
This is a randomized, open-label, phase I clinical study evaluating the systemic pharmacokinetics and safety of atropine sulfate eye drops in healthy Chinese volunteers.Three concentrations will be investigated, each concentration group must contain both male and female subjects, and each subject receives only one concentration of atropine sulfate eye drop in this study.
The three treatment arms are:
Atropine sulfate dose A (low concentration)
Atropine sulfate dose B (medium concentration)
Atropine sulfate dose C (high concentration)
This is the only study on the registry with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited as lead sponsor.
First submitted after Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited left Lee's Pharmaceutical Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be treated with atropine sulfate eye drop (at dosage Concentration A), administered once daily (QD).
Drug: Atropine sulfate eye drops
Subjects will be treated with atropine sulfate eye drop (at dosage Concentration B), administered once daily (QD).
Drug: Atropine sulfate eye drops
Subjects will be treated with atropine sulfate eye drop (at dosage Concentration C), administered once daily (QD).
Drug: Atropine sulfate eye drops
One drop once daily
Also known as: Atropine sulfate
Maximum concentration (Cmax)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Time of Cmax (Tmax)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Time of half-life (t1/2)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Area Under time-concentration Curve from 0 to last draw time (AUC0-t)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Area Under time-concentration Curve from 0 to infinity time (AUC(0-∞))
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Minimum concentration (Cmin)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Volume of distribution (Vd)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Elimination rate constant (Kel)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Clearance (CL)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Apparent Clearance (CL/F)
Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics
Time frame: From 1 hour before administration to 24 hours after administration
Slit-lamp eye examination results change from baseline to Day 7
Evaluate the anterior segment of the eye, including the eyelids, cornea, conjunctiva, anterior chamber, iris and lens, and record abnormalities
Time frame: on Day 0 and Day 7
Fundoscopy eye examination results change from baseline to Day 7
Evaluate the condition of the fundus, including the vitreous body, optic disc, macula, peripheral retina and retinal blood vessels
Time frame: on Day 0 and Day 7
Intraocular pressure change from baseline to Day 7
Use non-contact tonometer to measure intraocular pressure
Time frame: on Day 0 and Day 7
Vision acuity change from baseline to Day 7
Using Best-corrected LogMAR scale
Time frame: on Day 0 and Day 7
The mean change of pupil diameter from baseline to Day 7
Use ophthalmic biometry equipment to measure pupil diameter
Time frame: on Day 0 and Day 7
The mean change of accommodation amplitude from baseline to Day 7
Use a Phoropter to measure the accommodation amplitude using the negative lens method
Time frame: on Day 0 and Day 7
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2023; primary completion for Jun 2023, 1 month later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine